Inspire Investing, LLC Revance Therapeutics, Inc. Transaction History

Inspire Investing, LLC

$959 Million
Q3 2024

A detailed history of Inspire Investing, LLC transactions in Revance Therapeutics, Inc. stock. As of the latest transaction made, Inspire Investing, LLC holds 78,055 shares of RVNC stock, worth $200,601. This represents 0.02% of its overall portfolio holdings.

Number of Shares

78,055

Previous 139,079 43.88%

Holding current value

$200,601

Previous $357,000 43.98%

% of portfolio

0.02%

Previous 0.04%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Oct 10, 2024	SELL	$2.57 - $2.57 $156,831 - $156,831	-61,024 Reduced 43.88%	78,055 $200,000
Q2 2024 Aug 12, 2024	BUY	$2.34 - $4.73 $154,250 - $311,796	65,919 Added 90.1%	139,079 $357,000
Q1 2024 May 07, 2024	BUY	$4.65 - $9.31 $137,849 - $275,994	29,645 Added 68.13%	73,160 $359,000
Q4 2023 Feb 12, 2024	BUY	$5.81 - $11.2 $98,322 - $189,537	16,923 Added 63.64%	43,515 $382,000
Q3 2023 Oct 26, 2023	BUY	$11.47 - $25.07 $162,311 - $354,765	14,151 Added 113.74%	26,592 $305,000
Q2 2023 Jul 31, 2023	BUY	$24.7 - $37.61 $98,231 - $149,574	3,977 Added 46.99%	12,441 $314,000
Q1 2023 Apr 24, 2023	SELL	$18.36 - $35.27 $79,572 - $152,860	-4,334 Reduced 33.86%	8,464 $272,000
Q4 2022 Jan 26, 2023	BUY	$18.32 - $30.66 $93,596 - $156,641	5,109 Added 66.45%	12,798 $0
Q3 2022 Nov 07, 2022	SELL	$14.33 - $28.47 $112,504 - $223,517	-7,851 Reduced 50.52%	7,689 $208,000
Q2 2022 Aug 10, 2022	BUY	$11.52 - $20.4 $38,200 - $67,646	3,316 Added 27.13%	15,540 $215,000
Q1 2022 Apr 21, 2022	SELL	$12.36 - $20.31 $39,341 - $64,646	-3,183 Reduced 20.66%	12,224 $238,000
Q4 2021 Feb 14, 2022	BUY	$12.46 - $27.87 $191,971 - $429,393	15,407 New	15,407 $251,000

Others Institutions Holding RVNC

# of Institutions

230

Shares Held

81.5M

Call Options Held

617K

Put Options Held

870K

View Full List

About Revance Therapeutics, Inc.

Ticker RVNC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 82,305,696
Market Cap $212M
Description
Revance Therapeutics, Inc., a biotechnology company, engages in the development, manufacture, and commercialization of neuromodulators for various aesthetic and therapeutic indications in the United States and internationally. The company's lead drug candidate is DaxibotulinumtoxinA for injection, which has completed phase III clinical trials fo...

More about RVNC

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Inspire Investing, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Inspire Investing, LLC with notifications on news.

Account

Inspire Investing, LLC Revance Therapeutics, Inc. Transaction History